Claremont CA (PRWEB) March 28, 2012
Synedgen VP of Research, Stacy Townsend PhD, has been invited to present recent research results on Synedgen’s proprietary wound treatment at the 112th General Meeting of American Society for Microbiology (ASM2012) in San Francisco on June 16.
The presentation entitled “A Novel Chitosan Derivative is Mucoadhesive and Reduces Binding of MRSA and Acinetobacter baumannii to Epithelial Cells” highlights research examining the ability of Synedgen's proprietary polysaccharide, SYN01, to protect tissue from these bacteria. Methicillin resistant staphylococcus aureus (MRSA) is a common drug-resistant bacteria generating growing concern for both hospital and community acquired infections. A. baumannii is an increasing threat to our deployed troops, and also is frequently present in the US hospital environment. The presentation demonstrates the ability of SYN01 used in a wound rinse to limit the invasion and attachment of A. baumannii and MRSA bacteria on epithelial cells, and to provide prolonged, residual reduction of bacterial binding when used as a pretreatment.
After an hour of pretreatment of human epithelial cells with SYN01, the treatment was removed and bacteria were added. Bacterial attachment and invasion were reduced up to 18-fold for MRSA and 20-fold for A. baumannii. A 10-fold reduction in MRSA invasion was maintained up to 5 hours after pretreatment was removed.
“These results demonstrate that our non-toxic SYN01 is protective to tissue against bacterial infection. The Synedgen technology could help prevent serious infections and complications due to A. baumannii and MRSA soft-tissue and respiratory infections,” remarked Townsend.
Bacterial infections are currently treated with antibiotics; however, more and more bacteria are becoming resistant to these treatments. "We believe that SYN01 provides a revolutionary mechanism to treat and prevent infection. For infection to occur, bacteria must adhere to tissue,” noted Synedgen President and COO, Shenda Baker. “SYN01 blocks the foothold bacteria need to create infection. Use of traditional antibiotics results in killing both the infectious bacteria and the good, commensal flora, as well as potentially contributing to bacterial resistance. Synedgen is devoted to developing products that address a critical national need with a novel, effective approach that moves away from antibiotics.”
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. This platform technology provides the foundation for preventing bacterial growth and disruption of biofilms in human and environmental applications. Product development is targeted to specifically address unmet needs for therapies that treat and prevent infections, primarily from bacteria that have developed resistance to traditional antibiotics.
Synedgen’s Corporate Headquarters and Research Laboratories are in Claremont CA; Synedgen’s Manufacturing Facility is in Honolulu HI. Additional information can be found at Synedgen’s web site at http://www.synedgen.com